Navigating CLL Treatments During COVID-19

This chapter explores the AMPLIFI trial and its significance for patients with chronic lymphocytic leukemia (CLL) amidst the COVID-19 pandemic, particularly focusing on the risks faced by unvaccinated individuals. It discusses innovative treatment regimens, including Vennobizumab, acalabrutinib, and venetoclax, while examining their efficacy and tolerability in various patient demographics. The chapter also sheds light on the future of CLL treatment, including the emergence of new therapies like perturbrutinib and the strategic management of refractory cases.